The study involves patients who have End-Stage Kidney Disease and require dialysis before their transplant. These patients will be receiving kidneys from deceased donors through either Donation after Circulatory Death or Donation after Brain Death. The treatment involves receiving either ravulizumab or placebo through an intravenous infusion. The medication or placebo will be given to patients who meet specific medical requirements determined by their healthcare providers.

The study will track how long patients need to remain on dialysis after their transplant and monitor their kidney function. Researchers will observe patients for 90 days after their transplant to evaluate how well the treatment works. During this time, they will measure how quickly patients can stop requiring dialysis and how well their new kidney functions.

Participants in the study will be randomly assigned to receive either ARGX-117 or a placebo, which looks like the treatment but does not contain the active substance. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will take place over several weeks, with regular check-ups to monitor the health and kidney function of the participants.

The main goal is to assess how well the transplanted kidney is working 24 weeks after the transplant. Other aspects being monitored include the number of participants who experience delayed graft function, the duration of any dialysis treatment needed, and overall safety outcomes. The study will also look at how the body processes ARGX-117 and any potential immune responses to the treatment. The results will help determine if ARGX-117 is a safe and effective option for improving kidney function in transplant recipients at risk for delayed graft function.